Research progress of intestinal flora in lung cancer and chronic obstructive pulmonary disease

Jing Liu[a], Ruilin Sun[b,*]

The Affiliated Guangdong Second Provincial General Hospital of Jinan University, Guangzhou, Guangdong, 510317, China
[a]liujing990212@126.com, [b]sunruilin213@126.com
*Corresponding author

Keywords: Gut Microbiota, Lung Cancer, Chronic Obstructive Pulmonary Disease, Gut-Lung Axis, Microbiome

Abstract: This review explores the emerging role of gut microbiota in lung cancer and Chronic Obstructive Pulmonary Disease (COPD), emphasizing the gut-lung axis's integral role in these diseases. Lung cancer, the leading cause of cancer-related mortality, and COPD, a prevalent chronic respiratory condition, share common risk factors and pathophysiological pathways that may be influenced by the gut microbiota. Through a synthesis of current research, this article highlights the differences in gut microbiota composition observed in patients with lung cancer and COPD compared to healthy individuals, and discusses the potential mechanisms by which these microbial populations might impact disease development and progression. The review also delves into the promising therapeutic implications of modulating gut microbiota, including dietary interventions, probiotics, prebiotics, and fecal microbiota transplantation, as adjunctive treatments for these respiratory diseases. Future research directions are proposed, focusing on the need for a deeper understanding of the gut-lung axis and the translation of these findings into clinical practice. This review underscores the significance of gut microbiota in respiratory diseases and points towards a new frontier in personalized medicine, where microbiome modulation could complement traditional treatment approaches.

1. Introduction

The human gut microbiota, a complex and dynamic population of microorganisms residing in the gastrointestinal tract, has emerged as a critical player in the maintenance of health and the pathogenesis of various diseases. This diverse microbial community, composed predominantly of bacteria, but also including viruses, fungi, and protozoa, engages in a symbiotic relationship with its host, influencing a wide range of physiological processes. The gut microbiota plays a pivotal role in nutrient absorption, metabolism, and the modulation of the immune system, thereby maintaining a delicate balance between health and disease. Disruptions in the composition or function of the gut microbiota, known as dysbiosis, have been implicated in a multitude of conditions, ranging from gastrointestinal disorders to systemic diseases such as diabetes, obesity, and cardiovascular diseases.

In recent years, a growing body of evidence has shed light on the intriguing connections between

the gut microbiota and respiratory diseases, notably lung cancer and chronic obstructive pulmonary disease (COPD). Lung cancer, the leading cause of cancer-related deaths worldwide, is a multifaceted disease characterized by uncontrolled cell growth in lung tissues. This malignancy, predominantly caused by smoking, is often diagnosed at an advanced stage, leading to a poor prognosis. On the other hand, COPD, a progressive lung disease marked by airflow limitation, is primarily attributed to long-term exposure to harmful gases or particulate matter, most commonly from tobacco smoke. Both lung cancer and COPD share common risk factors and pathophysiological pathways, hinting at potential overlapping mechanisms in their development and progression.

The exploration of the gut-lung axis, a bidirectional communication pathway between the gut and lung microbiomes, has opened new horizons in understanding these respiratory conditions. The gut microbiota can influence lung health through various mechanisms, including immune system modulation, production of metabolites, and regulation of inflammatory responses. Conversely, lung diseases can also impact gut microbiota composition, creating a complex interplay that could amplify disease progression. This concept has stimulated considerable interest in deciphering the role of gut microbiota in the etiology and progression of lung cancer and COPD. Such research holds promise not only in enhancing our understanding of these diseases but also in identifying novel therapeutic targets and strategies. By manipulating the gut microbiota, either through diet, probiotics, prebiotics, or fecal microbiota transplantation, there is potential to modulate disease outcomes, offering a new avenue in the management of lung cancer and COPD[1].

The rationale for studying the role of gut microbiota in lung cancer and COPD is multifaceted. Firstly, it offers an opportunity to uncover novel pathogenic mechanisms that could explain the onset and progression of these diseases. Secondly, understanding the gut-lung axis could lead to the development of biomarkers for early detection and monitoring of lung cancer and COPD. Lastly, and perhaps most importantly, this research could pave the way for innovative therapeutic approaches, potentially transforming the management of these debilitating diseases. As we delve deeper into the complex world of microbiota and their systemic effects, we stand on the cusp of a new era in medical science, one that promises to redefine our approach to disease and health.

2. Gut Microbiota: Basics and Overview

The gut microbiota, a complex ecosystem residing in the human gastrointestinal tract, is composed of trillions of microorganisms, including bacteria, archaea, viruses, and fungi, with bacteria being the most extensively studied. This microbial community is incredibly diverse, varying significantly among individuals due to factors like genetics, diet, age, and environmental influences. The major bacterial phyla in a healthy adult gut are Firmicutes and Bacteroidetes, with others like Actinobacteria, Proteobacteria, and Verrucomicrobia also present in smaller proportions. This composition is not static; it evolves throughout an individual's life, influenced by various internal and external factors, creating a unique microbial fingerprint[2].

The functions of the gut microbiota are vast and critical for maintaining overall health. It plays a fundamental role in the digestion and absorption of nutrients, particularly those that are not easily digested by the human gut, like certain fibers, producing short-chain fatty acids (SCFAs) such as butyrate, propionate, and acetate in the process. These SCFAs have been shown to have multiple beneficial effects, including providing energy to colonocytes, regulating lipid and glucose metabolism, and exerting anti-inflammatory properties. Moreover, the gut microbiota is crucial in the development and function of the immune system. It helps in the maturation of immune cells and the development of oral tolerance, preventing the body from overreacting to non-harmful antigens. The microbiota also plays a role in protecting against pathogens by competing for nutrients and producing antimicrobial substances.

Beyond local gastrointestinal effects, the influence of gut microbiota extends to systemic health, impacting various organs and systems. This widespread impact is exemplified in the gut-lung axis, a bidirectional communication pathway linking the gut and lung microbiomes. The gut-lung axis suggests that alterations in the gut microbiota can influence lung health and vice versa. This interaction is mediated through various mechanisms, including immune modulation, where gut microbes influence systemic immune responses that can affect lung health. Microbial metabolites like SCFAs can enter the bloodstream and influence distant organs, including the lungs, by modulating immune cell function and inflammatory responses. Additionally, the gut microbiota can influence the lung microbiota directly through microaspiration or indirectly by shaping systemic immune responses[3].

The concept of the gut-lung axis has gained significant attention in the context of respiratory diseases. For instance, dysbiosis in the gut has been associated with inflammatory lung conditions like asthma, COPD, and lung cancer. The mechanisms are multifaceted, involving alterations in immune regulation, enhanced systemic inflammation, and potential changes in the lung microbiota itself. Understanding these connections is pivotal, as it opens up new avenues for therapeutic interventions targeting the gut microbiota to potentially mitigate respiratory diseases.

In summary, the gut microbiota is a complex and dynamic entity with far-reaching effects on human health. Its composition and functions are integral not only to gastrointestinal health but also to systemic wellbeing, including the health of the respiratory system. The exploration of the gut-lung axis reveals a fascinating interplay between distant organ systems, mediated by the gut microbiota, and underscores the potential of targeting the gut microbiota for therapeutic purposes in respiratory diseases. This field, though still in its infancy, holds immense promise for revolutionizing our understanding and treatment of various conditions, bridging gaps between different areas of medicine.

3. Lung Cancer and Gut Microbiota

Lung cancer, one of the most prevalent and deadly cancers globally, presents in two primary forms: non-small cell lung cancer (NSCLC), accounting for approximately 85% of cases, and small cell lung cancer (SCLC), which is more aggressive but less common. Risk factors for lung cancer are well-established, with smoking being the most significant. Other factors include exposure to radon gas, asbestos, and certain air pollutants, as well as genetic predispositions. Despite advances in treatment and detection, the prognosis for lung cancer remains poor, often due to late-stage diagnosis.[4]

The intersection of gut microbiota and lung cancer is an emerging area of research, driven by the growing understanding of the gut-lung axis. Recent studies have begun to uncover associations between the gut microbiota and lung cancer, suggesting that the composition and diversity of the gut microbiome might influence lung cancer risk and progression. For example, some research has found differences in the gut microbiota composition between lung cancer patients and healthy individuals, with certain bacterial populations either enriched or depleted in patients with lung cancer. These differences in microbiota composition might influence the host's immune response or metabolic pathways, potentially affecting cancer development[5].

Several potential mechanisms through which the gut microbiota may influence lung cancer development and progression have been proposed. One key mechanism is through the modulation of systemic inflammation. Chronic inflammation is a well-known risk factor for many types of cancer, including lung cancer. Gut microbiota can influence systemic inflammation levels through the production of metabolites like SCFAs and the modulation of pro-inflammatory and anti-inflammatory cytokines. Another mechanism is through the impact of gut microbiota on the host's immune system. The microbiota plays a crucial role in shaping both innate and adaptive immunity, and imbalances in gut microbial communities can lead to dysregulation of immune responses, potentially affecting

cancer surveillance and the efficacy of immune-based therapies. Additionally, gut bacteria can metabolize dietary components and drugs, producing metabolites that might have carcinogenic or anticarcinogenic effects.

The potential of the gut microbiota to affect the efficacy of cancer therapies, particularly immunotherapies, has also garnered significant interest. Studies have shown that the composition of the gut microbiota can influence the response to immunotherapy in lung cancer patients. Certain bacterial populations have been associated with improved response to checkpoint inhibitors, a class of drugs that boosts the immune system's response against cancer cells. This finding suggests that modulating the gut microbiota could potentially enhance the effectiveness of lung cancer treatments.

In summary, the relationship between lung cancer and gut microbiota is an area of growing research interest, with evidence suggesting that the gut microbiome may play a role in the development, progression, and treatment of lung cancer. Understanding the intricate interactions between the gut microbiota and lung cancer could open up new avenues for prevention, diagnosis, and therapy. Future research in this field promises to provide deeper insights into the complex interplay between our internal microbial ecosystems and cancer, potentially leading to novel strategies for combating this challenging disease.

4. Chronic Obstructive Pulmonary Disease (COPD) and Gut Microbiota

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disorder characterized by persistent respiratory symptoms and airflow limitation due to airway and/or alveolar abnormalities, primarily caused by significant exposure to noxious particles or gases. The most common symptoms include chronic cough, sputum production, and dyspnea, which often worsen over time. Tobacco smoking is the leading cause of COPD globally, although other factors like air pollution, occupational dust and chemicals, and genetic predispositions (like alpha-1 antitrypsin deficiency) also contribute to its development. COPD is a major cause of chronic morbidity and mortality worldwide, representing a significant public health challenge due to its increasing prevalence and the chronic nature of the disease.

Recent research has begun to elucidate the role of gut microbiota in COPD, revealing intriguing connections. Studies have identified differences in the gut microbiome composition between COPD patients and healthy individuals, suggesting that gut dysbiosis may be associated with the disease. These differences often manifest as reduced microbial diversity and alterations in specific bacterial populations. For instance, an increase in Proteobacteria and a decrease in Firmicutes have been reported in some COPD patients. This altered microbiota composition could potentially influence the progression and severity of COPD through several mechanisms.

One primary mechanism is the modulation of systemic and pulmonary inflammation. Gut microbiota can regulate systemic immune responses, which may affect lung inflammation and tissue damage in COPD. Microbial metabolites, especially short-chain fatty acids (SCFAs), are key mediators in this process. SCFAs, produced through the fermentation of dietary fibers by gut bacteria, have anti-inflammatory properties and can modulate immune cell function. A decrease in SCFA-producing bacteria in COPD patients could lead to increased systemic inflammation, exacerbating pulmonary symptoms. Additionally, the gut-lung axis suggests that changes in the gut microbiota can influence the lung microbiome, potentially affecting the lung's immune environment and response to pathogens.

Another potential link between gut microbiota and COPD is through the modulation of the gut barrier function. An altered gut microbiota can lead to increased gut permeability (leaky gut), allowing microbial products and metabolites to enter the circulation. This translocation of microbial products can trigger systemic immune responses that may worsen lung inflammation in COPD.

Furthermore, the gut microbiota's role in metabolizing dietary components and pharmaceuticals could also influence COPD progression[6]. Certain microbial metabolites may have protective or harmful effects on lung tissue, and the metabolism of medications by gut bacteria could affect drug efficacy and toxicity.

Emerging research also suggests that gut microbiota may play a role in the response to COPD treatments, particularly those involving anti-inflammatory and antibiotic therapies. The composition of the gut microbiota could influence the effectiveness and side effects of these treatments, indicating the potential for microbiota-targeted therapies in COPD management.

In conclusion, the relationship between COPD and gut microbiota is an area of active research, with growing evidence suggesting that the gut microbiome plays a role in the development, progression, and treatment of COPD. Understanding this complex interaction could lead to novel therapeutic strategies, such as microbiota modulation, to improve outcomes in COPD patients. Future research is needed to further elucidate these connections and translate them into clinical practice, potentially offering new hope for individuals suffering from this debilitating disease.

5. Interplay Between Gut Microbiota, Lung Cancer, and COPD

The intricate interplay between gut microbiota, lung cancer, and Chronic Obstructive Pulmonary Disease (COPD) presents a fascinating confluence of pathways and mechanisms, revealing deep connections in the human body's ecosystem. Both lung cancer and COPD are major respiratory diseases with distinct pathologies but share common risk factors, such as tobacco smoke and environmental pollutants, that may also influence the gut microbiome. Emerging research suggests that gut microbiota might play a significant role in modulating the risk and progression of these diseases through various mechanisms, bridging the gap between gastrointestinal and respiratory health.

Central to the relationship between gut microbiota and these respiratory diseases is the concept of the gut-lung axis, where the gut microbiota influences lung health and vice versa. In lung cancer, gut microbiota may affect the disease's development and progression through its role in systemic immunity and inflammation. Certain microbial profiles in the gut are associated with heightened systemic inflammation, a known risk factor for cancer development, including lung cancer. Additionally, gut microbiota can influence the efficacy of lung cancer therapies, particularly immunotherapies. Studies have shown variations in the response to immunotherapies based on the composition of gut microbiota, suggesting that modulating the gut microbiome could enhance treatment outcomes.

In the context of COPD, the gut microbiota appears to influence disease progression primarily through its impact on systemic and pulmonary inflammation and immune response. Dysbiosis in the gut can lead to increased systemic inflammation, exacerbating the inflammatory processes in the lungs that characterize COPD[7]. Moreover, the gut microbiota's role in metabolic processes and the integrity of the gut barrier also impacts COPD. Changes in microbial metabolites and increased gut permeability can contribute to systemic inflammation and immune dysregulation, potentially worsening COPD symptoms and progression.

Interestingly, there are shared pathways and mechanisms through which the gut microbiota impacts both lung cancer and COPD. Both diseases involve dysregulated immune responses and chronic inflammation, and gut microbiota can modulate these processes systemically. Additionally, shared environmental risk factors, such as smoking, can simultaneously influence the gut microbiome and the risk of both diseases. This suggests a potential overlapping influence of gut microbiota on these seemingly distinct respiratory conditions.

Moreover, the impact of gut microbiota on drug metabolism and the response to medications used

in lung cancer and COPD presents another layer of complexity. The microbiome's ability to metabolize drugs can affect the efficacy and toxicity of treatments for both conditions, highlighting the potential for personalized medicine approaches that consider individual microbiome profiles. The exploration of probiotics, prebiotics, and dietary interventions to modulate gut microbiota also opens up new avenues for adjunct therapies in lung cancer and COPD management[8].

In summary, the interplay between gut microbiota, lung cancer, and COPD underscores the profound influence of our internal microbial ecosystem on systemic health and disease. This complex interaction points to the gut microbiota as a potential key player in the development, progression, and treatment of these major respiratory diseases. The growing body of research in this area not only enhances our understanding of lung cancer and COPD but also holds promise for novel therapeutic strategies that leverage the modulation of gut microbiota. Future research is poised to further unravel these connections, potentially leading to groundbreaking approaches in the prevention and management of lung cancer and COPD.

6. Therapeutic Implications and Future Directions

The burgeoning research on the interplay between gut microbiota and respiratory diseases like lung cancer and COPD unveils promising therapeutic implications and paves the way for future directions in treatment and management. Modulating the gut microbiota through dietary changes, probiotics, prebiotics, and fecal microbiota transplantation (FMT) emerges as a potential adjunctive therapy to improve outcomes in these diseases. Dietary interventions that promote a healthy gut microbiome may reduce inflammation and positively impact lung health[9]. Probiotics and prebiotics, aimed at restoring or maintaining a beneficial microbiota composition, hold promise in modulating the immune response and reducing inflammation, potentially alleviating symptoms and slowing disease progression in COPD and lung cancer. FMT, though still in its nascent stages in this context, offers a radical approach to reset the gut microbiota, with preliminary studies suggesting potential benefits in various health conditions.

Future research in this field is poised to deepen our understanding of the gut-lung axis and translate these findings into clinical practice. Key areas of focus include identifying specific bacterial strains or microbiome profiles that influence lung cancer and COPD, understanding the precise mechanisms by which the gut microbiota impacts these diseases, and determining the efficacy and safety of microbiota-targeted therapies[10]. Personalized medicine approaches, which consider individual differences in microbiome composition, could lead to more tailored and effective treatments for respiratory diseases.

Moreover, exploring the interaction between gut microbiota and pharmaceuticals used in treating lung cancer and COPD will be crucial. Understanding how the microbiome affects drug metabolism and response could optimize treatment regimens and reduce adverse effects. As we move forward, integrating microbiome research into clinical trials and developing guidelines for microbiota-modulating interventions will be vital steps in harnessing the full therapeutic potential of this research[11].

7. Conclusion

This review has delved into the intricate relationship between the gut microbiota and two significant respiratory diseases, lung cancer and COPD, highlighting a burgeoning field of research with substantial implications for understanding, managing, and potentially treating these conditions. The concept of the gut-lung axis, central to this discussion, underscores the profound interconnectedness of different bodily systems and how alterations in the gut microbiota can have far-reaching effects, extending beyond the gut to impact lung health.

In lung cancer and COPD, the gut microbiota emerges not just as a bystander but as a potential influencer, capable of affecting disease development, progression, and response to treatment. The differences in microbiota composition observed in patients with these respiratory diseases compared to healthy individuals point towards a complex interplay where microbial populations may either exacerbate or mitigate disease processes. Understanding these dynamics opens a new window into the pathophysiology of lung cancer and COPD, offering fresh perspectives that challenge traditional views of these diseases.

The potential therapeutic implications of these findings are particularly promising. The possibility of manipulating the gut microbiota through diet, probiotics, prebiotics, and even fecal microbiota transplantation presents a novel approach to complement existing treatment modalities. However, the translation of these findings from bench to bedside requires careful and rigorous research. Future studies need to focus on elucidating the precise mechanisms of the gut-lung axis, identifying specific microbial targets, and assessing the efficacy and safety of microbiota-centered therapies.

As we advance, the integration of microbiome research into respiratory medicine could herald a new era of personalized medicine, where treatments are tailored not just to the genetic makeup of individuals but also to their unique microbial profiles. The journey to fully understand and harness the power of the gut microbiota in lung cancer and COPD is just beginning, promising exciting developments in the years to come.

Acknowledgements

References

[1] De Nuccio, F. et al. Gut–lung Microbiota interactions in chronic obstructive pulmonary disease (COPD): potential mechanisms driving progression to COPD and epidemiological data[J]. Lung, 2022, 200(6): 773-781.
[2] Song, W. et al. Imbalance of gut microbiota is involved in the development of chronic obstructive pulmonary disease: a review [J]. Biomedicine & Pharmacotherapy, 2023, 165: 115150.
[3] De Rubis, G. et al. Applications and advancements of nanoparticle-based drug delivery in alleviating lung cancer and chronic obstructive pulmonary disease[J]. Naunyn-Schmiedeberg's Archives of Pharmacology, 2023: 1-41.
[4] Wang, H. et al. The Function and Molecular Mechanism of Commensal Microbiome in Promoting Malignant Progression of Lung Cancer[J]. Cancers, 2022, 14(21): 5394.
[5] Lim, E. Y. et al. Gut Microbiome as a Possible Cause of Occurrence and Therapeutic Target in Chronic Obstructive Pulmonary Disease [J]. Journal of Microbiology and Biotechnology, 2023, 33(9): 1111.
[6] Ashique, S. et al. Short Chain Fatty Acids: Fundamental mediators of the gut-lung axis and their involvement in pulmonary diseases [J]. Chemico-Biological Interactions, 2022: 110231.
[7] Liu, Y. et al. The role of mitochondrial quality control in chronic obstructive pulmonary disease[J]. Laboratory Investigation, 2023: 100307.
[8] Li, N. et al. Gut Microbiota Dysbiosis and Chronic Obstructive Pulmonary Disease: A Question of Chicken and Egg [J]. American Journal of Respiratory and Critical Care Medicine, 2023, 208(11): 1238-1240.
[9] Tian, J. et al. Effect of hyperthermia on intestinal microecology, immune function, and progression-free survival in patients with advanced unresectable lung adenocarcinoma[J]. Scientific Reports, 2023, 13(1): 17223.
[10] Li, N. et al. The gut microbiome as a potential source of non-invasive biomarkers of chronic obstructive pulmonary disease [J]. Frontiers in Microbiology, 2023, 14: 24-35.
[11] Prasanthan, T. A. et al. Deducing the Interplay between Gut Flora and Respiratory Diseases: A New Therapeutic Strategy? [J]. Indian Journal of Microbiology, 2023, 63(1): 101-117.